RMBV takes 50% of Egypt's ATCO Pharma in $50M deal
What's the deal? RNAF III, a fund managed by North Africa-focused investment firm RMBVDealroom has a profile for this one. Try Dealroom →, has agreed to acquire a 50% stake in Egyptian drugmaker ATCO Pharma in a growth equity investment valued at $50 million, according to a source cited by Zawya. Zilla CapitalDealroom has a profile for this one. Try Dealroom → served as exclusive financial advisor to ATCO.
The structure: RMBV will buy a mix of newly issued and existing shares, giving it joint control alongside founder Dr. Ahmed Aboul Naga, who stays on as chief executive officer. Completion remains subject to conditions, including approval from the Egyptian Competition Authority.
What's the endgame? ATCO, which makes more than 150 pharmaceutical products and exports to over 10 countries including Saudi Arabia and Nepal, plans to broaden its human and veterinary medicine portfolio, speed up new launches, and expand across the region. It has more than 160 drug compounds in development.
Why now? The deal marks RMBV's first investment in Egypt's veterinary pharmaceutical sector. Ahmed Badr El-Din, managing partner at RMBV, described animal health as "a key component of the region's protein supply" and said the firm aims to help build "a leading regional platform in veterinary pharmaceuticals and specialized human medicines."
The signal: Egypt's pharma sector is drawing a cluster of private-equity interest, from AdeniaDealroom has a profile for this one. Try Dealroom →'s move on cosmeceutical maker ParkvilleDealroom has a profile for this one. Try Dealroom → to Admaius backing Minapharm's biotech expansion. The backdrop is a growing, policy-prioritised domestic industry: Egypt's drug authority reported a 2025 market value of EGP 422 billion and exports of about $1.3 billion, as the country pushes to localise production and lift exports.
Read more: technotime.net
Image credit: Generated with Gemini
